“…For example, Ibritumomab tiuxetan is an 90 Y-labeled mAb that binds specifically to CD20 (1, 2), a transmembrane protein expressed exclusively on both normal B cells and certain B cell -derived tumor cells, resulting in localization of mAb to tumor sites where 90 Y emits h-radiation capable of killing cells adjacent to the target cell (2). The benefit of this type of therapy is that tumor cells that do not express the target protein (e.g., CD20) can still be eliminated; however, exposure of healthy tissues to radiation is a major concern (3,4). Effective tumor doses have been shown to be highly variable in clinical trials, ranging from 16 to 14,000 cGy, with toxicity reported following exposure of liver, stomach, bowel, kidneys, and lungs to doses ranging from 1,000 to 8,000 cGy, delivered by therapeutic doses of a variety of radionuclides (4).…”